Adaptimmune Therapeutics Azioni (NASDAQ: ADAP)

Adaptimmune Therapeutics

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

AdaptHealth Corp

Adaptive Hedged Multi-Asset Income ETF

Adaptive Alpha Opportunities ETF

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Core ETF

Adapti Inc

Adappter Token

Press Releases

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Reports Q2 Financial Results and Provides Business Update

ADAP

AFFX

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Annovis Bio

AlphaTON Capital

BioAtla

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Elutia

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Kezar Life Sciences

LAVA Therapeutics

Moleculin Biotech

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

Lunai Bioworks

Rein Therapeutics

Senti Biosciences

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Exicure

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Adaptimmune Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO